PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Neuropsychiatric Events With Subcutaneous Foslevodopa/Foscarbidopa: 19.2% Incidence, Few Discontinuations

foslevodopafoscarbidopalevodopacontinuous subcutaneous infusionParkinson's diseaseneuropsychiatric adverse eventshallucinationspsychosisimpulse control disorderdevice-aided therapyprospective registryreal-world evidenceneurology Neurology / Neuropharmacology

Background Information

Subcutaneous infusion in Parkinson's shows mild neuropsychiatric risks.

Understanding neuropsychiatric adverse events in Parkinson's patients receiving continuous infusion helps optimize treatment and patient safety. In a cohort of 214 patients, 19.2% experienced neuropsychiatric adverse events, mainly mild to moderate, with only 2.3% requiring device removal. The study highlights low risk of severe events with foslevodopa/foscarbidopa infusion, underlining the importance of monitoring patients with impulse control disorders (ICDs). Continuous subcutaneous infusion is generally safe for Parkinson's patients, but requires monitoring for impulse control disorder risks.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Campo-Caballero D, Rodriguez-Antiguedad J, Puig-Davi A, Ruiz-Martinez J, Vinagre-Aragón A, Mondragón E, Vilella LP, López-Ariztegui N, Caballol N, González-Ortega G, Cabo I, Ramos RG, Legarda I, Blázquez-Estrada M, Sánchez-Alonso P, Mir P, Fábrega JCR, Martinez SM, Sauco MÁ, Santos-García D, DATs‐PD GETM Spanish Registry Group

Citation: Campo-Caballero D, Rodriguez-Antiguedad J, Puig-Davi A, et al. Neuropsychiatric Adverse Events Associated With Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Clinical Practice: A Multicenter Study. European journal of neurology. 2026;33(7):e70693. doi:10.1111/ene.70693

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.